Blood FlowGA-17bNCT06426823
The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes
A study testing GIPR antagonist / study tool in people with Blood Flow, run by University of Copenhagen at 1 site in Denmark.
Trial summary
This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with type 2 diabetes. Read more about this study
- Who is it for?
- Ages 20 to 80 years
- Conditions the study is for
- Blood Flow
- What is being tested?
- GIPR antagonist / study tool
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 10 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Nov 2023to 16 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Type 2 diabetes
- BMI 20-35 kg/m^2
- Age 20-80
Who cannot join
- Not MRI-compatible implants
- Claustrophobia
- Abnormal kidney or liver function
- Anemia
- Planned weight loss or change in diet
- Hypertension
- Other conditions that could be expected to affect the primary or secondary outcomes
Trial locations and contacts
1 site in 1 country.
About this study
This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with type 2 diabetes.
Read the detailed description
Each participant will attend four independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose/water): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2).
MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines, pancreas, and bones.
- Conditions
- Blood Flow
- Being tested
- Saline / placebo, GIPR antagonist / study tool
- Keywords
- Gut hormones, GIP, Physiology, Type 2 diabetes
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Saline / placeboOther
NaCl (9 mg/ml)
GIPR antagonist / study toolOther
GIP(3-30)NH2
| Study group | Role | What they receive |
|---|---|---|
| Saline and oral water (SAL-WAT) | Placebo comparator | Saline infusion, oral water ingestion Receives: Other: Saline / placebo |
| Saline infusion and oral glucose ingestion (SAL-GLU) | Active comparator | Saline infusion, oral glucose ingestion Receives: Other: Saline / placebo |
| GIP(3-30)NH2 infusion and oral water ingestion (GIA-WAT) | Experimental | GIPR antagonist infusion, oral water ingestion Receives: Other: GIPR antagonist / study tool |
| GIP(3-30)NH2 infusion and oral glucose ingestion (GIA-GLU) | Experimental | GIPR antagonist infusion, oral glucose ingestion Receives: Other: GIPR antagonist / study tool |
What is being measured
The primary outcome is the main question the study is designed to answer.
Redistribution of splanchnic blood flow in the vessel mesenteric superior artery (functional MRI)
Measued with phase-contrast MRI in ml/min
Measured: 80 minutes
Secondary outcomes (9)
GIP levels
Radioimmuno assay on plasma blood sample (pmol/L)
Measured: 80 minutes
GIP(3-30)NH2 levels
Radioimmuno assay on plasma blood sample (nmol/L)
Measured: 80 minutes
Glucose
Bedside measurement of whole blood sample (mmol/L)
Measured: 80 minutes
C-peptide
Electrochemiluminescence immunoassay of plasma blood sample (pmol/L)
Measured: 80 minutes
Insulin
Electrochemiluminescence immunoassay of plasma blood sample (pmol/L)
Measured: 80 minutes
Glucagon
Radioimmuno assay on plasma blood samples (pmol/L)
Measured: 80 minutes
Blood flow in portal vein
Measued with phase-contrast MRI in ml/min
Measured: 80 minutes
Blood flow in coeliac trunc
Measued with phase-contrast MRI in ml/min
Measured: 80 minutes
Blood flow in hepatic artery
Measued with phase-contrast MRI in ml/min
Measured: 80 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 May 2024
- Study start1 Nov 2023
- Primary completion16 Mar 2026
- Study completion16 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Blood FlowStudies of the same condition, open and under way.
- More trials run by University of CopenhagenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Single blind, placebo controlled, randomized, crossover study
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Copenhagen
- Sponsor type
- University, hospital or other
- Collaborators
- Copenhagen University Hospital, Rigshospitalet
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06426823
- Sponsor's protocol ID
- GA-17b
- Acronym
- GA-17b
- Status last verified
- May 2024
- First submitted
- 6 May 2024
- Last updated
- 18 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Will share upon requests
Publications
Rasmussen RS, Nielsen SW, Alstrup L, Larsson TSW, Hansen JK, Pedersen RP, Vestergaard MB, Haddock B, Johannesen HH, Larsson HBW, Holst JJ, Hartmann B, Rosenkilde MM, Asmar A, Andersen UB, Gasbjerg LS. GIP contributes to postprandial regulation of splanchnic blood supply in humans with type 2 diabetes: a randomised, single-blinded, placebo-controlled, crossover study. Diabetologia. 2026 Jul 2. doi: 10.1007/s00125-026-06788-1. Online ahead of print.
PubMed 42393405Gasbjerg LS, Ostergaard FH, Rasmussen RS, Langberg LS, Nielsen SW, Alstrup L, Larsson TSW, Andersen UB, Larsson HBW, Asmar A, Haddock B, Vestergaard MB. Reproducibility of Splanchnic Blood Flow Measured Using Phase-Contrast MRI. NMR Biomed. 2026 Aug;39(8):e70348. doi: 10.1002/nbm.70348.
PubMed 42373095
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT06426823
- Acronym / sponsor ID
- GA-17b / GA-17b
- Conditions
- Blood Flow
- Keywords
- Gut hormones, GIP, Physiology, Type 2 diabetes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- University of CopenhagenUniversity, hospital or other
- Collaborators
- Copenhagen University Hospital, Rigshospitalet
- Study start
- 1 Nov 2023 (actual)
- Primary completion
- 16 Mar 2026 (actual)
- Study completion
- 16 Mar 2026 (actual)
- First posted
- 23 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP(3-30)NH2 in patients with type 2 diabetes.
Detailed description
Each participant will attend four independent randomised experimental days in the MRI-scanner with intravenous infusion (hormone/placebo) and oral ingestion (glucose/water): An intravenous infusion of saline or GIP(3-30)NH2 starts at time point -20 minutes.The infusions are combined with an oral glucose tolerance test (75 gram of glucose dissolved in 250 ml water ingested orally) at time point 0 minutes on two of the experimental days (with and without GIP(3-30)NH2).
MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines, pancreas, and bones.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 4
- Model description
- Single blind, placebo controlled, randomized, crossover study
| Arm | Type | Receives |
|---|---|---|
| Saline and oral water (SAL-WAT) | Placebo comparator | Other: Saline / placeboSaline infusion, oral water ingestion |
| Saline infusion and oral glucose ingestion (SAL-GLU) | Active comparator | Other: Saline / placeboSaline infusion, oral glucose ingestion |
| GIP(3-30)NH2 infusion and oral water ingestion (GIA-WAT) | Experimental | Other: GIPR antagonist / study toolGIPR antagonist infusion, oral water ingestion |
| GIP(3-30)NH2 infusion and oral glucose ingestion (GIA-GLU) | Experimental | Other: GIPR antagonist / study toolGIPR antagonist infusion, oral glucose ingestion |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Type 2 diabetes
- BMI 20-35 kg/m^2
- Age 20-80
Key exclusion criteria (7 listed)
- Not MRI-compatible implants
- Claustrophobia
- Abnormal kidney or liver function
- Anemia
- Planned weight loss or change in diet
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Saline / placeboNaCl (9 mg/ml) | Other | Saline and oral water (SAL-WAT), Saline infusion and oral glucose ingestion (SAL-GLU) |
| GIPR antagonist / study toolGIP(3-30)NH2 | Other | GIP(3-30)NH2 infusion and oral glucose ingestion (GIA-GLU), GIP(3-30)NH2 infusion and oral water ingestion (GIA-WAT) |
Primary outcome
Redistribution of splanchnic blood flow in the vessel mesenteric superior artery (functional MRI)
Time frame: 80 minutes
Measued with phase-contrast MRI in ml/min
9 secondary outcomes
GIP levels
Time frame: 80 minutes
GIP(3-30)NH2 levels
Time frame: 80 minutes
Glucose
Time frame: 80 minutes
C-peptide
Time frame: 80 minutes
Insulin
Time frame: 80 minutes
Glucagon
Time frame: 80 minutes
Blood flow in portal vein
Time frame: 80 minutes
Blood flow in coeliac trunc
Time frame: 80 minutes
Blood flow in hepatic artery
Time frame: 80 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2026.
- Derived from this study: PubMed 42393405Rasmussen RS, Nielsen SW, Alstrup L, Larsson TSW, Hansen JK, Pedersen RP, Vestergaard MB, Haddock B, Johannesen HH, Larsson HBW, Holst JJ, Hartmann B, Rosenkilde MM, Asmar A, Andersen UB, Gasbjerg LS. GIP contributes to postprandial regulation of splanchnic blood supply in humans with type 2 diabetes: a randomised, single-blinded, placebo-controlled, crossover study. Diabetologia. 2026 Jul 2. doi: 10.1007/s00125-026-06788-1. Online ahead of print.
- Derived from this study: PubMed 42373095Gasbjerg LS, Ostergaard FH, Rasmussen RS, Langberg LS, Nielsen SW, Alstrup L, Larsson TSW, Andersen UB, Larsson HBW, Asmar A, Haddock B, Vestergaard MB. Reproducibility of Splanchnic Blood Flow Measured Using Phase-Contrast MRI. NMR Biomed. 2026 Aug;39(8):e70348. doi: 10.1002/nbm.70348.
- Individual participant dataSharing planned: Yes. Will share upon requests
Related trials for Blood Flow
Not yet recruitingPhase 4
Oral Switch in Bloodstream Infections in Immunocompromised Children
Bloodstream Infection, Bloodstream Infection Due to Central Venous Catheter
Not yet recruiting
Evaluation of an AI-Assisted Tool for CLABSI Surveillance at VA Medical Centers
Central Line-Associated Bloodstream Infection (CLABSI), Bacteremia
RecruitingObservational study
Studies of Blood Flow to the Brain During Thought
Healthy Volunteer
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Heart Failure, Heart Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing GIPR antagonist / study tool in people with Blood Flow, run by University of Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Redistribution of splanchnic blood flow in the vessel mesenteric superior artery (functional MRI) (time frame: 80 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06426823, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026.